Publications by authors named "C Caiazza"
Introduction: The Russo-Ukrainian War (RUW) poses a significant mental health burden, warranting a scoping review of the evidence to shed light on the unmet needs.
Methods: MEDLINE/PubMed and EMBASE databases were inquired from inception until September 1st, 2023, to address the following a-priori-formulated questions: i) "Which psychiatric population has been assessed? How did the conflict affect the functioning of people with established mental health conditions (e.g.
Tardive Dyskinesia (TD) can occur in people exposed to dopamine receptor antagonists (DRAs). Its clinical management remains challenging. We conducted a systematic review/random-effects network meta-analysis (NMA) searching PubMed/MEDLINE/PsycINFO/ClinicalTrials.
View Article and Find Full Text PDFSub-optimal response in schizophrenia is frequent, warranting augmentation strategies over treatment-as-usual (TAU). We assessed nutraceuticals/phytoceutical augmentation strategies via network meta-analysis. Randomized controlled trials in schizophrenia/schizoaffective disorder were identified via the following databases: PubMed, MEDLINE, EMBASE, Scopus, PsycINFO, CENTRAL, and ClinicalTrials.
View Article and Find Full Text PDFSleep medications often carry residual effects potentially affecting driving safety, warranting network meta-analysis (NMA). PubMed/EMBASE/TRID/Clinicaltrials.gov/WHO-ICTRP/WebOfScience were inquired for randomized controlled trials of hypnotic driving studies in persons with insomnia and healthy subjects up to 05/28/2023, considering the vehicle's standard deviation of lateral position - SDLP (Standardized Mean Difference/SMD) and driving impairment rates on the first morning (co-primary outcomes) and endpoint.
View Article and Find Full Text PDFArticle Synopsis
- Rituximab is a key chemotherapy drug for aggressive lymphomas like non-Hodgkin's lymphoma, often used in combination with chemotherapy (R-CHOP) as the first-line treatment.
- The study investigates IBTK's role in cancer progression, specifically its impact on the oncogene MYC in B-lymphomas.
- Findings suggest that silencing IBTK can enhance the anti-tumor effects of Rituximab, promoting cell death and potentially improving treatment outcomes for aggressive B-lymphomas.